INTERCEPT-MDS - Exploiting 3D organotypic niche models to dissect the cellular crosstalk between niche and haematopoietic stem/progenitor cells (HSPCs) in myelodysplastic syndromes (MDS). Dr. Hind Medyouf
Research · Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus. Germany > Frankfurt
1 full-time PhD position
HOST INSTITUTE: Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus. Germany > Frankfurt
RESEARCH PROFILE: First Stage Researcher (R1)
APPLICATION DEADLINE: 30 July 2021
EU RESEARCH FRAMEWORK PROGRAMME: HORIZON 2020
MARIE SKOLODOWSKA CURIE GRANT AGREEMENT NUMBER: 953407
 First Stage Researcher (R1) PhD candidate or equivalent. Early stage researcher with less than 4 years FTE research experience.
The Innovative Training Network (ITN) “INTERCEPT-MDS - Exploring cell-to-cell heterogeneity and exploiting epigenetic regulation for the interception of myeloid disease cells" is recruiting 1 highly motivated PhD candidate. The offered position is available with a duration of 36 months in the Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus (Frankfurt, Germany) under the supervision of Dr. Hind Medyouf. The position is funded as part of the Marie Skłodowska-Curie Actions (MSCA) Innovative Training Networks under the European Commission’s Horizon 2020 programme. MARIE CURIE GRANT AGREEMENT NUMBER: 953407
See more info at: https://ec.europa.eu/research/...
Scientific Project: Exploiting 3D organotypic niche models to dissect the cellular crosstalk between niche and haematopoietic stem/progenitor cells (HSPCs) in myelodysplastic syndromes (MDS).
The PhD candidate at Dr. Hind Medyouf´s research lab (https://georg-speyer-haus.de/s...) will combine experimental and computational approaches to dissect the cellular crosstalk between niche and haematopoietic stem cell/progenitors (HSPCs) in myelodysplastic syndromes (MDS) with the goal to identify niche dependencies that can be exploited for disease interception. The Project will make extensive use of innovative 3D Human Organotypic Marrow Environments (3DHOMEs) to functionally evaluate niche dependencies and perform screens to identify druggable modules that promote the fitness and progressive clonal dominance of malignant MDS cells. Results will be confirmed using patient-derived xenograft models and primary patient samples.
To achieve this the successful candidate will use a large panel of wet lab techniques, including primary cell culture, multiparameter flow cytometry, various imaging platforms, CRISPR/Cas9 mediated genetic engineering and animal work. Additionally, the candidate will use single cell RNA sequencing approaches, to carry out a comprehensive and spatially resolved analysis of the composition and priming of both the MDS and the stromal compartment. As such, preference will be given to candidate(s) with experience/background in computational science/bioinformatics.
To further broaden the expertise of the PhD candidate and support the project, two secondments of 3 months at GenomeScan B.V. (Leiden, The Netherlands) and 2 months at University of Bergen (Bergen, Norway), will be offered as an integral part of the PhD project.